Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
|
US |
|
I
|
IMI PLC
F:IMI1
|
UK |
|
T
|
Toll Brothers Inc
XMUN:TLK
|
US |
|
BMTC Group Inc
OTC:BMTCF
|
CA |
|
S
|
Shri Gang Industries and Allied Products Ltd
BSE:523309
|
IN |
|
S
|
Signetics Corp
KOSDAQ:033170
|
KR |
|
Nephros Inc
NASDAQ:NEPH
|
US |
|
OSE Immunotherapeutics SA
PAR:OSE
|
FR |
|
S
|
Shanghai Chinafortune Co Ltd
SSE:600621
|
CN |
|
Atland SA
PAR:ATLD
|
FR |
|
Newmark Group Inc
NASDAQ:NMRK
|
US |
|
P
|
Public Service Enterprise Group Inc
DUS:PSE
|
US |
|
N
|
NOS SGPS SA
F:PMV
|
PT |
|
S
|
Standard Supply AS
OSE:STSU
|
NO |
|
Toa Road Corp
TSE:1882
|
JP |
|
UMS Holdings Ltd
SGX:558
|
SG |
|
P
|
Pernod Ricard SA
XBER:PER
|
FR |
|
Schweizerische Nationalbank
SIX:SNBN
|
CH |
|
Santa Cruz County Bank
OTC:SCZC
|
US |
|
FAR Ltd
ASX:FAR
|
AU |
|
U
|
Union Semiconductor Hefei Co Ltd
SSE:688403
|
CN |
|
Shinpo Co Ltd
TSE:5903
|
JP |
|
Daiwa House Industry Co Ltd
TSE:1925
|
JP |
|
OneWater Marine Inc
NASDAQ:ONEW
|
US |
Wall St Price Targets
CBIO Price Targets Summary
Crescent Biopharma Inc (Pre-Reincorporation)
According to Wall Street analysts, the average 1-year price target for
CBIO is 31.21 USD with a low forecast of 27.27 USD and a high forecast of 36.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CBIO's stock price target?
Price Target
31.21
USD
According to Wall Street analysts, the average 1-year price target for
CBIO is 31.21 USD with a low forecast of 27.27 USD and a high forecast of 36.75 USD.
What is the Revenue forecast for Crescent Biopharma Inc (Pre-Reincorporation)?
Projected CAGR
77%
Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 8 years is 77%.